Loading...
XAMS
VVY
Market cap52mUSD
Apr 11, Last price  
1.77EUR
1D
-1.67%
1Q
-11.06%
Jan 2017
-89.98%
IPO
-92.38%
Name

Vivoryon Therapeutics NV

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
24.70%
Rev. gr., 5y
%
Revenues
-4m
21,0006,0000000000010,764,0000-3,620,000
Net income
-28m
L+0.66%
-16,307,000-18,720,000-9,929,000-11,437,000-13,505,000-13,891,000-8,009,000-7,737,000-7,823,000-16,510,000-12,655,000-28,156,000-28,342,000
CFO
-22m
L-1.16%
-14,321,000-12,040,000-8,526,000-10,589-12,147-13,255-12,117-6,994-11,608,000-14,012,000-11,257,000-21,794,000-21,541,000
Earnings
Jun 20, 2025

Profile

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.
URL
https://www.vivoryon.com/
IPO date
Oct 27, 2014
Employees
15
Domiciled in
DE
Incorporated in
NL

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
(3,620)
 
Cost of revenue
20,387
38,028
Unusual Expense (Income)
NOPBT
(24,007)
(38,028)
NOPBT Margin
663.18%
Operating Taxes
(234)
(199)
Tax Rate
NOPAT
(23,773)
(37,829)
Net income
(28,342)
0.66%
(28,156)
122.49%
Dividends
Dividend yield
Proceeds from repurchase of equity
26,346
35,247
BB yield
-12.82%
-15.51%
Debt
Debt current
38
94
Long-term debt
38
76
Deferred revenue
(1)
Other long-term liabilities
1,365
1,335
Net debt
(28,507)
(26,399)
Cash flow
Cash from operating activities
(21,541)
(21,794)
CAPEX
(14)
(13)
Cash from investing activities
(10,514)
(13)
Cash from financing activities
24,157
33,381
FCF
(22,705)
(38,079)
Balance
Cash
28,583
26,555
Long term investments
14
Excess cash
28,764
26,569
Stockholders' equity
(122,732)
(96,532)
Invested Capital
150,417
124,448
ROIC
ROCE
EV
Common stock shares outstanding
25,242
22,020
Price
8.14
-21.12%
10.32
-45.68%
Market cap
205,471
-9.58%
227,242
-40.20%
EV
176,964
200,843
EBITDA
(23,840)
(37,867)
EV/EBITDA
Interest
56
24
Interest/NOPBT